Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy
暂无分享,去创建一个
H. Saeki | T. Yokobori | N. Nakazawa | K. Kaira | M. Sakai | A. Sano | M. Sohda | T. Shiraishi | Takuhisa Okada | Naoya Ozawa | Yuta Shibasaki | Hiroomi Ogawa | Chika Komine | K. Shirabe | Ikuma Shioi | K. Osone | Kunihiko Suga
[1] Sami I. Alzarea,et al. mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer , 2022, International journal of molecular sciences.
[2] A. Indini,et al. NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets , 2022, International journal of molecular sciences.
[3] Y. Wada,et al. Induction of CTH expression in response to amino acid starvation confers resistance to anti-LAT1 therapy in MDA-MB-231 cells , 2022 .
[4] E. Rakha,et al. Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer , 2021, Scientific Reports.
[5] G. Sheu,et al. L-Type Amino Acid Transporter 1 Regulates Cancer Stemness and the Expression of Programmed Cell Death 1 Ligand 1 in Lung Cancer Cells , 2021, International journal of molecular sciences.
[6] K. Shirabe,et al. High L-Type Amino Acid Transporter 1 Levels Are Associated with Chemotherapeutic Resistance in Gastric Cancer Patients , 2021, Oncology.
[7] Y. Kanai. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. , 2021, Pharmacology & therapeutics.
[8] G. Bergers,et al. The metabolism of cancer cells during metastasis , 2021, Nature Reviews Cancer.
[9] A. Dubrovska,et al. Amino Acid Transporters on the Guard of Cell Genome and Epigenome , 2021, Cancers.
[10] G. J. Yoshida. The Harmonious Interplay of Amino Acid and Monocarboxylate Transporters Induces the Robustness of Cancer Cells , 2021, Metabolites.
[11] Y. Kanai,et al. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor , 2020, Cancer science.
[12] Anas M. Saad,et al. Colorectal Cancer Epidemiology: Recent trends and Impact on Outcomes. , 2020, Current drug targets.
[13] Yanning Liu,et al. MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway , 2020, Journal of Experimental & Clinical Cancer Research.
[14] Sung-Bae Kim,et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.
[15] A. K. Murugan. mTOR: Role in cancer, metastasis and drug resistance. , 2019, Seminars in cancer biology.
[16] N. Tomita,et al. Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] K. Shirabe,et al. Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer , 2019, AntiCancer Research.
[18] Zhenghua Zhang,et al. Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K/Akt/MTOR pathway. , 2019, Frontiers in bioscience.
[19] Dirk Mossmann,et al. mTOR signalling and cellular metabolism are mutual determinants in cancer , 2018, Nature Reviews Cancer.
[20] K. Shirabe,et al. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma , 2018, Cancer Chemotherapy and Pharmacology.
[21] S. Bröer,et al. Amino acid homeostasis and signalling in mammalian cells and organisms , 2017, The Biochemical journal.
[22] David M. Sabatini,et al. mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.
[23] D. Hsu,et al. Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis , 2017, PloS one.
[24] Y. Kanai,et al. Prognostic impact of LAT1 and CD98 expression in cutaneous angiosarcoma. , 2017, Neoplasma (Bratislava).
[25] H. Kuwano,et al. Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma , 2016, Cancer science.
[26] T. Oyama,et al. Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma , 2016, Journal of surgical oncology.
[27] K. Katanoda,et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. , 2015, Japanese journal of clinical oncology.
[28] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[29] T. Oyama,et al. Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. , 2015, American journal of translational research.
[30] T. Oyama,et al. Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer , 2014, British Journal of Cancer.
[31] H. Endou,et al. LAT1 Is a Critical Transporter of Essential Amino Acids for Immune Reactions in Activated Human T Cells , 2013, The Journal of Immunology.
[32] K. Guan,et al. Amino acid signalling upstream of mTOR , 2013, Nature Reviews Molecular Cell Biology.
[33] T. Hickish,et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] D. Kerr,et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.
[35] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.
[36] T R Fleming,et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.
[37] T. Fleming,et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.